Founded by recognized leaders in intrathecal therapies, CNS Therapeutics developed and brought to market safe, high-quality pharmaceuticals for site-specific delivery to the central nervous system. CNS was acquired by Covidien in 2012.
Xenon is a clinical genetics-based drug development company. Independently and through partnerships with leading global pharmaceutical companies, Xenon identifies and validates new targets for drug development and converts that knowledge into innovative and differentiated medicines. Its programs focus on indications of important unmet medical needs, including pain, anemia, iron overload, metabolic and cardiovascular disease. Xenon’s pipeline of products spans discovery through to Phase 2 clinical trials. The company is headquartered in Burnaby, British Columbia.
USDS independently evaluates medical laboratory diagnostic tests to validate quality, speed development, assure alignment with regulatory requirements, guide regulatory pathway strategy, and inform reimbursement decisions. The performance, intended use, and risk assessment of diagnostic tests are certified through the company’s DxSTANDARDS process, which uses standards and methods based on the consensus of regulatory, industry, and academic experts.
Trius Therapeutics (TSRX) is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company is addressing the need for novel therapeutics to treat multi-drug-resistant bacterial infections as they become more resistant to currently marketed drugs. Trius was acquired by Cubist in 2013.
Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. The Transcept drug-delivery system enhances the absorption of drug active agents, reduces first-pass drug inactivation by the liver, and decreases the time required for the onset of drug action, potentially to a level approaching that of parenteral administration.
Tesaro (TSRO) is an oncology-focused biopharmaceutical company dedicated to
improving the lives of cancer patients by developing and providing safer
and more effective therapeutics and supportive care products. Since its
founding, Tesaro in-licensed Rolapitant from OPKO Health, as well as
small molecule inhibitors of Anaplastic Lymphoma Kinase from Amgen.
Tesaro plans to develop one or more compounds for oncology indications,
including the treatment of patients with non-small-cell lung cancer.
Sera Prognostics develops simple blood tests that predict preterm birth, preeclampsia and other pregnancy complications. Using these tests, physicians can make early and accurate assessment of pregnancy complication risks so they can effectively manage their patients’ pregnancies.
ReVision Optics develops custom optical solutions dedicated to vision correction. Its first product is the Vue+ inlay, a unique patented refractive surgery solution which improves near vision that has been lost by presbyopia, the eye's natural aging process. Vue+ is approved in Europe, has its CE mark, and ReVision is actively pursuing regulatory approvals and market opportunities worldwide.
RadioRx discovers and develops compounds sourced and adapted from the aerospace industry for treating cancer and other indications.
QuatRx Pharmaceuticals is focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.